×
About 28,185 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  9,587 results

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute...
https://doi.org/10.1038/s41375-021-01487-9
Leukemia Sunthankar KI, Jenkins MT et. al.

Dec 4th, 2021 - Mutations in isocitrate dehydrogenase 2 (IDH2) have been noted to impact cellular differentiation in addition to DNA and histone methylation. However, little is known about the impact of IDH2 mutations on intracellular signaling. Using an isogenic...

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT02632721

Dec 3rd, 2021 - Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I ...

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

KAT6A and ENL form an epigenetic transcriptional control module to drive critical leuke...
https://doi.org/10.1158/2159-8290.CD-20-1459
Cancer Discovery; Yan F, Li J et. al.

Dec 3rd, 2021 - Epigenetic programs are dysregulated in acute myeloid leukemia (AML) and help enforce an oncogenic state of differentiation arrest. To identify key epigenetic regulators of AML cell fate, we performed a differentiation-focused CRISPR screen in AML...

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AM...
https://clinicaltrials.gov/ct2/show/NCT05144243

Dec 3rd, 2021 - Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how ...

see more →

Guidelines  11 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  28 results see all →

Clinicaltrials.gov  581 results

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT02632721

Dec 3rd, 2021 - Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I ...

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
https://clinicaltrials.gov/ct2/show/NCT03915379

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT05143996

Dec 3rd, 2021 - Patients will receive a single dose of CLN-049 and will be followed for safety for 28 days. CLN-049 will be administered IV.

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AM...
https://clinicaltrials.gov/ct2/show/NCT05144243

Dec 3rd, 2021 - Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how ...

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
https://clinicaltrials.gov/ct2/show/NCT00258427

Dec 2nd, 2021 - OBJECTIVES: Primary Determine whether the incidence of neutrophil engraftment is acceptable in high-risk patients with Fanconi's anemia treated with busulfan, cyclophosphamide, fludarabine, and antithymocyte globulin followed by allogeneic hematop...

see more →

News  1,063 results

Alvocidib followed by cytarabine and mitoxantrone shows clinical activity in MCL-1-dependent R/R AML
https://www.mdedge.com/hematology-oncology/article/249262/aml/alvocidib-followed-cytarabine-and-mitoxantrone-shows-clinical

Dec 1st, 2021 - Key clinical point: Alvocidib followed by cytarabine and mitoxantrone (ACM) was clinically active and well tolerated in patients with myeloid cell leukemia-1 (MCL-1)-dependent relapsed/refractory (R/R) acute myeloid leukemia (AML). Major finding:.

Antimicrobial prophylaxis prevents life-threatening infections in children with AML receiving chemotherapy
https://www.mdedge.com/hematology-oncology/article/249260/aml/antimicrobial-prophylaxis-prevents-life-threatening

Dec 1st, 2021 - Key clinical point: Antimicrobial prophylaxis significantly reduced rates of bloodstream infection (BSI), invasive fungal infection (IFI), and febrile neutropenia (FN) in pediatric patients with acute myeloid leukemia (AML) receiving chemotherapy.

Newly diagnosed AML: Optimization of idarubicin and cytarabine induction based on D5-PBCR
https://www.mdedge.com/hematology-oncology/article/249258/aml/newly-diagnosed-aml-optimization-idarubicin-and-cytarabine

Dec 1st, 2021 - Key clinical point: Optimization of a traditional induction regimen with idarubicin and cytarabine (IA) with additional homoharringtonine according to day 5 peripheral blast clearance rate (D5-PBCR) ³99. 55% (D5-PBCR −) is feasible in patients with.

Outpatient neutropenia management appears possible without excess risk in pediatric AML
https://www.mdedge.com/hematology-oncology/article/249255/aml/outpatient-neutropenia-management-appears-possible-without

Dec 1st, 2021 - Key clinical point: Outpatient vs. inpatient neutropenia management after chemotherapy was not associated with an increased bacteremia incidence, treatment delays, or worse health-related quality of life (HRQoL) in pediatric patients with acute my.

Cases Tick Upward; Opioid Retailers Held Accountable; Do Vaccines Reduce Long COVID?
https://www.medpagetoday.com/infectiousdisease/covid19/95856

Nov 24th, 2021 - Note that some links may require registration or subscription. Our Daily COVID-19 Update will not appear this Thursday or Friday in observance of the Thanksgiving holiday. Look for its return on Monday, November 29. As COVID cases continue to surg...

see more →

Patient Education  4 results see all →